Navigation Links
Quest Diagnostics Reports Second Quarter 2013 Financial Results
Date:7/18/2013

strategically aligned, accretive acquisitions.  In addition, we continued to refocus on diagnostic information services through our ongoing portfolio review. In the second quarter, we completed the sale of HemoCue, and used the proceeds to repurchase shares. We repurchased $405 million of our shares in the second quarter, bringing year to date share repurchases to $467 million. This morning, we completed the sale of the ibrutinib royalty rights to Royalty Pharma for $485 million in cash. We expect to use the proceeds to drive shareholder value, consistent with our capital deployment strategy."

First Half PerformanceRevenues from continuing operations were $3.6 billion for the first six months of 2013, 4.9% below the prior year. Adjusted income from continuing operations was $307 million, or $1.95 per diluted share, compared to $353 million, or $2.20 per diluted share, in 2012. On a reported basis, income from continuing operations was $268 million, or $1.71 per diluted share, compared to $331 million, or $2.06 per diluted share, in 2012.

Adjusted operating income from continuing operations for the first half of 2013 was $579 million, or 16.1% of revenues, compared to $667 million, or 17.6% of revenues, for 2012. On a reported basis, operating income from continuing operations was $516 million, or 14.3 % of revenues, compared to $631 million, or 16.7% of revenues, in 2012. Cash provided by operations was $255 million, compared to $412 million in the first six months of 2012.

Outlook for 2013 For 2013, the company estimates results from continuing operations, before special items, as follows:

  • Revenues now expected to be 1% to 2% below the prior year, compared to previous guidance approximating the prior year level;
  • Earnings per diluted share now expected to be between $4.35 to $4.50, compared to previous guidance of between $4.35 and $4.55;
  • Cash provided by operations to approach $1 billion, compared to previo
    '/>"/>

  • SOURCE Quest Diagnostics Incorporated
    Copyright©2012 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16

    Related biology technology :

    1. Quest Diagnostics CE Marks Simplexa™ Test for Cytomegalovirus for Sale in Europe
    2. Questcor Pharmaceuticals to Present at the Oppenheimer Healthcare Conference on December 13, 2011
    3. A 50-year quest to isolate the thermoelectric effect is now over: Magnon drag unveiled
    4. Survey Reveals Paternity Questions Loom for More Than One in 10 Americans
    5. S.E.D. Labs to be Acquired by Quest Diagnostics
    6. Quest Diagnostics STRATIFY JCV™ First FDA Market Authorized Antibody-based Blood Test to Help Stratify PML Risk in Multiple Sclerosis Patients
    7. Quest Diagnostics Reports Fourth Quarter 2011 Financial Results; Provides Guidance for 2012
    8. Questcor Pharmaceuticals to Present at the Leerink Swann Global Healthcare Conference on February 16, 2012
    9. Mars, Incorporated Answers Question: How Does Feeding People and Pets Nurture Science and Discovery? At TEDMED 2012
    10. Quest Diagnostics Announces C9orf72 Genetic Test for ALS (Lou Gehrigs Disease)
    11. Questcor Pharmaceuticals Expands Repurchase Program
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:8/19/2014)... 19, 2014 In November 2012, the European ... Evaluation Report (PBRER) in a new PSUR – responding to ... benefit-risk profile of a drug. Adopted in many regions, the ... Present a comprehensive and critical analysis of new or ... Highlight any new evidence of the potential benefits of ...
    (Date:8/19/2014)... AZ (PRWEB) August 19, 2014 Sales ... launch of its online sales skills training course ... sales skills. , MedTech clinical staff spend the majority ... a hospital, standalone medical center, or physician practice – ... staff. But why stop there? Sales Horizons believes clinical ...
    (Date:8/18/2014)... , Aug. 18, 2014 /PRNewswire/ - SQI Diagnostics Inc. ... commercializes proprietary technologies and products for advanced microarray diagnostics, ... on Friday, August 22 at 2:00 pm ET.  ... CEO, will provide a brief review of SQI,s recent ... , a diagnostics industry veteran recently appointed to the ...
    (Date:8/18/2014)... devices with unprecedented efficiency and data storage ... use built-in electric polarizations to read and ... most popular data-driven technology. But ferroelectrics must ... including a curious habit of "forgetting" stored ... U.S. Department of Energy,s Brookhaven National Laboratory ...
    Breaking Biology Technology:Top Five Best Practices for Developing Your Periodic Benefit Risk Evaluation Report (PBRER), New Webinar Hosted by Xtalks 2Sales Horizons Launches a New Online Sales Training Course for MedTech Clinical Staff to Develop Their Sales Skills 2Sales Horizons Launches a New Online Sales Training Course for MedTech Clinical Staff to Develop Their Sales Skills 3SQI Diagnostics Announces Investor Conference Call with Dr. Allan Pronovost 2SQI Diagnostics Announces Investor Conference Call with Dr. Allan Pronovost 3Promising ferroelectric materials suffer from unexpected electric polarizations 2Promising ferroelectric materials suffer from unexpected electric polarizations 3Promising ferroelectric materials suffer from unexpected electric polarizations 4
    ... Provides HIV-Resistant Immune CellsRICHMOND, Calif., Feb. 3 Sangamo ... that its collaborators at the University of Pennsylvania ... evaluate SB-728-T for the treatment of HIV/AIDS. Based on ... has been shown in an animal model of ...
    ... face of a recession is no small feat for any company. ... Sudberg called "being in the right place at the right time" and ... ... CA (PRWEB) February 2, 2009 -- Sidney Sudberg, Founder, CEO and Chief ...
    ... 2 Since the cloning of Dolly the ... has been considered a promising way to generate human, patient-specific ... eggs has led to efforts to substitute animal oocytes. However, ... Volume 11, Number 2, 2009 issue of Cloning and ...
    Cached Biology Technology:Sangamo BioSciences Initiates Phase 1 Trial of CCR5-ZFP Therapeutic to Treat HIV/AIDS 2Sangamo BioSciences Initiates Phase 1 Trial of CCR5-ZFP Therapeutic to Treat HIV/AIDS 3Sangamo BioSciences Initiates Phase 1 Trial of CCR5-ZFP Therapeutic to Treat HIV/AIDS 4Sangamo BioSciences Initiates Phase 1 Trial of CCR5-ZFP Therapeutic to Treat HIV/AIDS 5Sangamo BioSciences Initiates Phase 1 Trial of CCR5-ZFP Therapeutic to Treat HIV/AIDS 6Sangamo BioSciences Initiates Phase 1 Trial of CCR5-ZFP Therapeutic to Treat HIV/AIDS 7Alkemists Labs Wins Nutrition Business Journal's 2008 Industry Growth Award 2Alkemists Labs Wins Nutrition Business Journal's 2008 Industry Growth Award 3Animal Eggs Not Suitable Substitutes to Produce Stem Cells 2Animal Eggs Not Suitable Substitutes to Produce Stem Cells 3
    (Date:8/20/2014)... Using population-based screening outcomes of approximately 3 million ... four researchers at the University of Massachusetts Medical School, ... (SCID) can be successfully implemented across public health newborn ... in the Aug. 20 issue of the Journal ... showed the rate of SCID in newborns is higher ...
    (Date:8/20/2014)... Ore. -- When are athletes who have suffered concussions ... Oregon study has found that high school athletes who ... 60 days experience a significant regression in their abilities ... The regression, as seen in changes in their balance ... 19 athletes. Ten of the 12 had returned to ...
    (Date:8/20/2014)... bags could one day be made out of cocoa, ... now reporting. The novel process they developed and their ... agricultural and plastic waste problems, appear in the ACS ... Bayer and colleagues at the Italian Institute of Technology ... 2012, its production reached 288 million tons worldwide, but ...
    Breaking Biology News(10 mins):Newborn screening expansion offers early diagnosis and treatment to infants with SCID 2Newborn screening expansion offers early diagnosis and treatment to infants with SCID 3Recovery reversal seen in Oregon study of returning concussed athletes 2Recovery reversal seen in Oregon study of returning concussed athletes 3
    ... SPRING HARBOR, N.Y. (Nov. 12, 2008) For ... for written exams on theoretical concepts, it can be ... skills used in the clinic. The third edition ... for these daunting practical-skills tests, Clinical Skills for ...
    ... is proud to acknowledge the work of 12 outstanding ... new ideas, recognize leadership in gerontological teaching and service, ... award presentations will take place at GSA,s 61st Annual ... 2008, in National Harbor, MD , at the ...
    ... November 09, 2008─Bronx, NY─ In a breakthrough study appearing ... researchers at Albert Einstein College of Medicine of Yeshiva ... viewing individual breast cancer cells for several days at ... Lipper Biophotonics Center, provides detail on how cancer cells ...
    Cached Biology News:New book helps medical students master clinical skills 2GSA congratulates 2008 award winners 2GSA congratulates 2008 award winners 3Einstein researchers develop a new way to study how breast cancer spreads 2Einstein researchers develop a new way to study how breast cancer spreads 3
    Mouse monoclonal [1C6/2] to Rad17 ( Abpromise for all tested applications). entrezGeneID: 5884 SwissProtID: Q9UPF5...
    ... Zeba Desalt Spin Columns contain a ... that offers exceptional desalting and protein-recovery characteristics ... containing as low as 25 g/ml of ... recovery and > 95% retention of salts ...
    Rabbit polyclonal to VPAC2 ( Abpromise for all tested applications). entrezGeneID: 7434 SwissProtID: P41587...
    ... Synthetic peptide corresponding to ... Antigen Family: Regulator ... Subfamily: not assigned-Regulator ... Storage: Long term: ...
    Biology Products: